Around the middle of October this year, the world's major hepatitis B pharmaceutical companies have begun hbv scientific conference, and the specific content of the meeting has not yet been announced. During the year, hepatitis B new drug research progress and latest pipeline updates of hepatitis B were under research by two domestic and foreign pharmaceutical companies.
From: Enanta's latest pipeline
Hepatitis B two pharmaceutical companies are following up on new drugs, including RNA destabilizers and surface antigen inhibitors
I. American biopharmaceutical companies (enanta pharmaceuticals)
This is a pharmaceutical company focusing on the research and development of small molecule drugs for viral infections and liver diseases, and the pharmaceutical company is currently having two new drugs for hepatitis B with different mechanisms of action, namely edp-514, the core inhibitor of hepatitis B virus virus, and oral hbvrna destabilizer.
About EDP-514 (IB Phase): Since the beginning of this year, Enanta has published positive data for two Phase IB studies of EDP-514, one for chronic HBV patients who have been treated with nucleoside retrotransgenase inhibitors, and the other for patients with viremia who are not currently receiving treatment;
About EDP-721 (Phase I): Enanta is pushing this RNA destable agent into bed development this year, and in late August 2021, the company launched the Phase I clinical study of EDP-721, which is expected to obtain preliminary trial data for the Phase I study in the first half of next year. The drug candidate is thought to have the potential to become an important component of the all-oral drug to achieve a functional cure for chronic HBV.
From: Fujian Guangshengtang recently announced
2. Fujian Guangshengtang Pharmaceutical
According to the latest announcement from Guangshengtang, the company's current research and development projects for new drugs under development aimed at clinically curing hepatitis B are being promoted, including gst-hg131/gst-hg121 and gst-hg141.
gst-HG141, a core protein inhibitor, has completed phase ia clinical trials, and phase ib was approved in early April 2021 and is actively underway.
gst-hg131, is a hepatitis B surface antigen inhibitor, but also the first hepatitis B surface antigen inhibitor approved for clinical trials in China, its safety and tolerability to subjects have been completed, and is being further clinical research preparations.
gst-hg121, also a hepatitis B surface antigen inhibitor, has shown good safety and efficacy in preclinical studies, and is currently actively undergoing preclinical sample preparation.
From: Recent announcement by Guangshengtang, Fujian Province
Xiaofan Health Conclusion: The above progress in the development of new drugs for slow hepatitis B in the world comes from the update of the HBV pipeline of Enanta Company and the recent announcement of Fujian Guangshengtang. At present, the scientific community considers the removal of hepatitis B surface antigen (hbsag) from serum as an ideal antiviral endpoint for patients with chronic hepatitis B. At the same time, the level of serum HBSAG is also an indicator of the transcriptional activity of covalent closed cyclic DNA (CCCDNA) in the liver.
Although the surfacular antigen secretion pathway is partially independent of hepatitis B virus replication, the secretion of hepatitis B surface antigens can indirectly provide the number of infected hepatocytes.
From the perspective of the global research strategy of researchers focusing on hepatitis B drug development, simply put, there are many steps in the HBV replication life cycle, and the previous nucleoside (acid) analogues (nas) and interferon (ifn) mainly inhibit one of these steps or play an immunomodulatory role, and the mechanism of action of these new drugs for hepatitis B in research is different from nas or ifn, they inhibit more other steps in the HBV life cycle.
There is uncertainty in the research and development of new drugs, and recently, the content of the HBV scientific conference of the remaining foreign pharmaceutical companies has not yet announced the research progress, and if there is progress, it will be updated in time. Have a great life!